Biotech Values

[DewDiligence]

SAGE—(+40%/AH)—receives unsolicited $7.22/sh cash-buyout offer_from BIIB:

https://www.businesswire.com/news/home/20250110340262/en/

Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.

In the AH session, the stock is trading almost 10% above the proposed buyout price—i.e. investors think BIIB’s $7.22 offer is just the opening salvo.